| Target Price | HK$22.88 |
| Price | HK$8.97 |
| Potential |
155.06%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Ascletis Pharma Inc 2027 .
The average Ascletis Pharma Inc target price is HK$22.88.
This is
155.06%
register free of charge
HK$32.55
262.88%
register free of charge
HK$14.00
56.06%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Ascletis Pharma Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ascletis Pharma Inc stock has an average upside potential 2027 of
155.06%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million HK$ | 2.37 | 19.25 |
| 58.00% | 712.09% | |
| EBITDA Margin | -21,175.11% | -2,397.99% |
| 25.20% | 88.68% | |
| Net Margin | -17,762.87% | -2,167.55% |
| 24.31% | 87.80% |
5 Analysts have issued a sales forecast Ascletis Pharma Inc 2026 . The average Ascletis Pharma Inc sales estimate is
This results in the following potential growth metrics:
5 Ascletis Pharma Inc Analysts have issued a net profit forecast 2026. The average Ascletis Pharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | -0.43 | -0.42 |
| 22.86% | 2.33% | |
| P/E | negative | |
| EV/Sales | 334.61 |
5 Analysts have issued a Ascletis Pharma Inc forecast for earnings per share. The average Ascletis Pharma Inc EPS is
This results in the following potential growth metrics and future valuations:
Ascletis Pharma Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


